(Q48404055)

11 February 2018

title

Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats (English)

1 reference

11 February 2018

1 reference

Izurieta-Sánchez P

1

1 reference

11 February 2018

Sarre S

series ordinal

2

1 reference

11 February 2018

Ebinger G

series ordinal

3

1 reference

11 February 2018

Michotte Y

series ordinal

4

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 July 1998

1 reference

11 February 2018

European Journal of Pharmacology

published in

1 reference

11 February 2018

volume

353

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

33-42

1 reference

11 February 2018

Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Does levodopa aggravate Parkinson's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Cholinergic-anticholinergic antagonism in parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Muscarinic M1, M2 receptor binding. Relationship with functional efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Activation of nigral M1 and M2 muscarinic receptors produces opposing effects on striatal 3,4-dihydroxyphenylacetic acid measured by in vivo voltammetry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Neurotransmitters and neuromodulators in the basal ganglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Relationship between tardive dyskinesia, l-Dopa-induced hyperkinesia and parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Cholinergic stimulation of rostral and caudal substantia nigra pars compacta produces opposite effects on circling behavior and striatal dopamine release measured by brain microdialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Muscarinic receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Muscarinic receptor stimulation increases the spontaneous [3H]GABA release in the rat substantia nigra through muscarinic receptors localized on striatonigral terminals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Dopamine receptor supersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

The striatal cholinergic interneuron: synaptic target of dopaminergic terminals?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Dopamine receptor gene expression by enkephalin neurons in rat forebrain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Cholinergic modulation of [3H]dopamine release from dendrosomes of rat substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Chronic blockade of muscarinic cholinergic receptors by systemic trihexyphenidyl (Artane®) administration modulates but does not mediate the dopaminergic regulation of striatal prepropeptide messenger RNA expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Adipsia and Aphagia after 6-Hydroxydopamine Induced Degeneration of the Nigro-striatal Dopamine System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900393-8

10.1016/S0014-2999(98)00393-8

7 January 2021

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018